Randomized Phase II Study of Dose-Adjusted Epoch-Rituximab-Bortezomib Induction Followed by Bortezomib Maintenance Versus Observation in Untreated Mantle Cell Lymphoma With Microarray Profiling and Proteomics
Latest Information Update: 13 Oct 2022
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 13 Sep 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Status changed from active, no longer recruiting to completed.
- 21 Sep 2021 Planned End Date changed from 11 Aug 2021 to 11 Aug 2022.